Trainguy1
$IRON Disc Medicine expects to have a lot of news and information to share in Q4:
- Bitopertin (Erythropoietic Porphyrias - EPP/XLP): Topline data from the fully enrolled Phase 3 APOLLO Trial are expected in Q4 2026, which will serve as the basis to support traditional approval.
- DISC-0974 / Selcodibar (Myelofibrosis Anemia): Topline Phase 2 RALLY-MF data updates and an End-of-Phase 2 meeting with the FDA are anticipated in H2 2026 / Q4 2026.
- DISC-3405 (Polycythemia Vera & Sickle Cell Disease): Initial clinical data from the Phase 2 study in polycythemia vera and the Phase 1b study in sickle cell disease are expected in Q4 2026.
3
